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Targeting the Substrate Preference of a Type I Nitroreductase To
Develop Antitrypanosomal Quinone-Based Prodrugs
Belinda S. Hall,* Emma Louise Meredith, and Shane R. Wilkinson
Queen Mary Pre-Clinical Drug Discovery Group, School of Biological & Chemical Sciences, Queen Mary University of London, London, United Kingdom
Nitroheterocyclic prodrugs are used to treat infections caused by Trypanosoma cruzi and Trypanosoma brucei. A key compo-
nent in selectivity involves a specific activation step mediated by a protein homologous with type I nitroreductases, enzymes
found predominantly in prokaryotes. Using data from determinations based on flavin cofactor, oxygen-insensitive activity, sub-
strate range, and inhibition profiles, we demonstrate that NTRs from T. cruzi and T. brucei display many characteristics of their
bacterial counterparts. Intriguingly, both enzymes preferentially use NADH and quinones as the electron donor and acceptor,
respectively, suggesting that they may function as NADH:ubiquinone oxidoreductases in the parasite mitochondrion.We ex-
ploited this preference to determine the trypanocidal activity of a library of aziridinyl benzoquinones against bloodstream-form
T. brucei. Biochemical screens using recombinant NTR demonstrated that several quinones were effective substrates for the par-
asite enzyme, havingKcat/Km values 2 orders of magnitude greater than those of nifurtimox and benznidazole. In tests against T.
brucei, antiparasitic activity mirrored the biochemical data, with the most potent compounds generally being preferred enzyme
substrates. Trypanocidal activity was shown to be NTR dependent, as parasites with elevated levels of this enzyme were hyper-
sensitive to the aziridinyl agent. By unraveling the biochemical characteristics exhibited by the trypanosomal NTRs, we have
shown that quinone-based compounds represent a class of trypanocidal compound.
Over 10 million people are infected with Trypanosoma cruziand Trypanosoma brucei, the causative agents of Chagas’ dis-
ease and human African trypanosomiasis, respectively (8, 52). To-
gether, these pathogens are responsible for around 40,000 deaths
per year and represent a major public health problem in the re-
gions of the world least able to deal with the associated economic
burden (54). As a consequence of concerted surveillance, insect
vector control, and improved housing programs, there has been a
significant decline in the prevalence of infections by both species.
However, as a result of blood transfusion, organ transplantation,
illicit drug usage, and population migration, these trypanosomi-
ases are emerging as a problem in areas of nonendemicity, includ-
ing in Europe and the United States (5, 22, 23, 60). Currently,
drugs are the only viable option to treat these diseases. For T. cruzi,
treatment is based on nifurtimox and benznidazole, whereas
suramin, pentamidine, melarsoprol, eflornithine, and nifurti-
mox-eflornithine combinational therapy are used against HAT
(64). In addition to the problems represented by toxicity, resis-
tance, and cost, therapy is further complicated by the fact that the
effectiveness of some drugs is dependent on the subspecies and the
disease stage. Therefore, there is an urgent requirement for alter-
native chemotherapies.
Quinone-based compounds encompass a range of molecules,
characterized by two carbonyl groups linked to a carbocyclic back-
bone. They are widely distributed in nature and are able to partic-
ipate in a number of crucial biological oxidoreductase cascades.
Additionally, both natural and synthetic quinones have been ex-
tensively used in medicine as antimicrobial and anticancer agents,
functioning either as inhibitors of essential redox pathways or as
prodrugs. In the latter case, the compound must undergo activa-
tion by quinone reductases before mediating their cytotoxic ef-
fects. Quinone reductases can broadly be divided into two groups
based on the number of reducing equivalents transferred to their
target substrate. Some enzymes mediate the 1e reduction of the
quinone carbonyl oxygens to form an unstable semiquinone rad-
ical. Under hypoxic conditions, the radical then undergoes further
reduction to produce the hydroquinone derivative. However, in
the presence of O2, formation of the hydroquinone product is
inhibited, with the semiquinone radical undergoing futile cycling
to produce superoxide and regeneration of the parent compound
(42, 47). In contrast, other quinone reductases, typified by NAD-
(P)H:quinone oxidoreductase, catalyze the 2e reduction of the
quinone to form the hydroquinone directly (15, 33, 57). Interest-
ingly, expression of these enzymes in normal tissue is low but is
elevated in cancer cells, a difference that has been exploited in the
development of anticancer therapies (34). During the 2e reduc-
tion of the quinone to its hydroquinone form, a redistribution of
electrons occurs within the compound’s backbone that can lead to
exposure of a prodrug’s cytotoxic component. For azirinidyl an-
ticancer agents, such as mitomycin C, EO9, and AZQ, the cyto-
toxic agent remains attached to the hydroquinone core, whereas
in other compounds, for example, phosphoramidate mustards
and indolequinone-camptothecins, this “electronic switch” pro-
motes cleavage of specific bonds in the structure’s backbone, re-
sulting in compound fragmentation and drug release (11).
Trypanosomal screening programs using natural and synthetic
quinones have identified a number of lead compounds (31, 46).
However, the mechanism(s) by which such agents mediate their
antiparasitic activity is unclear. Based on in vitro enzyme studies
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and the belief that protozoan parasites have a limited enzymatic
capacity to metabolize reactive oxygen species, it had been postu-
lated that some quinones may function by inhibiting key essential
enzymes such as trypanothione reductase or lipoamide dehydro-
genase, while others are thought to induce oxidative stress within
the parasite (18, 19, 21, 29, 37, 51). However, no demonstration of
a functional link between the antiparasitic activity of any quinone-
based agent and a proposed protein target within the pathogen has
been reported and it is now well established that trypanosomatids
possess a series of novel enzymatic oxidative defense pathways.
In many regards, the situation concerning quinone reduc-
tion mirrors the confusion that surrounded investigations of
the trypanocidal mechanism of action of nifurtimox and ben-
znidazole. It is now clear that trypanosomes activate such nitro-
based drugs using a mitochondrially targeted, oxygen-insensitive
type I NTR, leading to the formation of cytotoxic reduction prod-
ucts (26, 27, 65). This class of oxidoreductase is largely restricted
to bacteria and absent from most eukaryotes, with a subset of
protozoan parasites being major exceptions. The differences be-
tween the pathogens and human host in NTR distribution are
believed to form the basis for the drug selectivity of nitrohetero-
cyclic prodrugs. Here, we show that TbNTR and TcNTR display
many of the characteristics displayed by their bacterial counter-
parts and reveal that both parasite enzymes have a preference for
quinone-based substrates. Exploiting this property, we evaluated
the trypanocidal activities of an aziridinyl 1,4-benzoquinone se-
ries, identifying several compounds that display high activity
against bloodstream-form T. brucei.
MATERIALS AND METHODS
Abbreviations. AZQ, 2,5-diaziridinyl-3,6-bis(carboethoxy-amino)-
1,4-benzoquinone: BCA, bicinchoninic acid; BSF, bloodstream form;
DCPIP, dichlorophenolindolephenol; DZQ, 2,5-diaziridinyl-1,4-ben-
zoquinone; FAD, flavin adenine dinucleotide; FMN, flavin mononuc-
lotide; GPDH, glycerol-3-phosphate dehydrogenase; HAT, human Af-
rican trypanosomiasis; IC50, drug concentration that inhibits cell
growth by 50%; IPTG, isopropyl--D-thiogalactopyranoside; MeDZQ,
2,5 dimethyl-3,6 diaziridinyl-1,4-benzoquinone; Ni-NTA, nickel-nitrilo-
triacetic acid; NTR, nitroreductase; NQO1, NAD(P)H:quinone oxidoreduc-
tase; RH1, 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoqui-
none; TbNTR, type I NTR from T. brucei; TcNTR, type I NTR from T.
cruzi; TZQ, triaziquone [2,3,5-tris(aziridin-1-yl)cyclohexa-2,5-diene-
1,4-dione].
Compounds. The compounds used in this study were obtained from
the following sources: nitrofurazone, nitrofurantoin, CB1954, ubiqui-
none 5, duroquinone, and DCPIP were purchased from Sigma-Aldrich.
Metronidazole was a gift from Nubia Boechat (Far Manguinhos, Rio de
Janeiro, Brazil), megazol from Mike Barrett (University of Glasgow), LH7
and LH37 from Longqin Hu (Rutgers University), and amino-824 from
Clifton Barry III (National Institute of Allergy and Infectious Diseases)
and Ujjini Manjunatha (Novartis Institute for Tropical Diseases, Singa-
pore). Benznidazole and nifurtimox were provided by Simon Croft (Lon-
don School of Hygiene and Tropical Medicine). The aziridinyl benzoqui-
nones (Table 1) were supplied by the Department of Therapeutics, NCI,
except for RH1, which was donated by Frank Guziec, Jr. (Southwestern
University, Georgetown, TX).
Parasite culturing. T. brucei brucei (Lister 427; clone 221a and a de-
rivative [2T1] engineered to constitutively express the tetracycline repres-
sor protein) BSF parasites were grown in modified Iscove’s medium at
37°C under a 5% CO2 atmosphere (2, 30). The 2T1 parasites transformed
to overexpress TbNTR were grown in the presence of 1 g ml1 phleo-
mycin and 2.5 g ml1 hygromycin (65).
Growth inhibition assays. T. brucei brucei BSF parasites were seeded
at 1  103 cells ml1 in 200 l of growth medium containing different
concentrations of aziridinyl benzoquinone. After incubation at 37°C for 3
days, 20 l alamarBlue (Invitrogen, Paisley, United Kingdom) was added
to each well and the plates were incubated for a further 8 to 16 h. Cell
densities were determined by monitoring the fluorescence of each culture
using a Gemini Fluorescent Plate Reader [Molecular Devices (UK) Ltd.,
Wokingham, United Kingdom] at excitation   530 nm, emission  
585 nm, and a filter cutoff at 550 nm, and the IC50 was established.
Expression constructs. A DNA fragment encoding the catalytic do-
main of TcNTR (amino acids 78 to 312) was amplified from T. cruzi Sylvio
X10/6 genomic DNA using the primers ggatccTGGATGCCATGAAACG
TGTA and aagcttTCAAAACTTTCCCCACCGAAC (lowercase type cor-
responds to restriction sites incorporated into the primers to facilitate
cloning). The product was digested using BamHI and HindIII and cloned
into the corresponding sites of pTrcHisC. Construction of the expression
vector containing the equivalent region from TbNTR is described else-
where (28).
Oligonucleotide site-directed mutagenesis was carried out using a
Stratagene QuikChange mutagenesis kit (Agilent Technologies, Stock-
port, United Kingdom) with pTrcHis-TcNTR as the template for DNA.
Amplifications were performed in accordance with the manufacturer’s
instructions using primers (Eurofins) to generate each of the desired mu-
tations. The forward primer sequences were R90A (GTGTAGTACACGA
GGCACGCTCCTGCAAGCG), K94A (GAGCGTCGCTCCTGCGCGCG
ATTTGACCCAAC), Q124A (GCTCCTACCGCCCTGAACTTAGCGCC
ATGGGTGG), and R302A (CCGTACGCAGCCCAGCATTTCCCACGA
AGC). The relevant substitution sites, incorporating the required base
change, are underlined.
Protein purification.His-tagged TcNTR (wild type and mutants) and
TbNTR were expressed and purified as described previously (28). Briefly,
overnight cultures of Escherichia coli BL21() containing the expression
plasmid were diluted 1:50 in NZCYM (Sigma-Aldrich) medium contain-
ing 100g ml1 ampicillin and grown for 2 to 4 h at 37°C. The culture was
transferred to 16°C for 30 min, and then protein expression was induced
by the addition of 100 M IPTG. Cultures were incubated at 16°C for a
further 20 h. Cells were formed into pellets and then lysed in a reaction
mixture consisting of 50 mM NaH2PO4 (pH 7.8) and 500 mM NaCl
TABLE 1 Structure of aziridinyl 1,4-benzoquinones used in this study
Compound NSC no. Structure
DZQ (1) 30706 R1 R2H
MeDZQ (2) 646714 R1 R2 CH3
RH1 (3) 697726 R1 CH2OH; R
2 CH3
AZQ (4) 182986 R1 R2 NHCOOCH2CH3
TZQ (5) 29215 R1 aziridinyl; R2H
6 95139 R1 R2 OCH3
7 18270 R1 R2 OCH2CH3
8 246111 R1 R2 NH2
9 220267 R1 R2 NHCH3
10 18269 R1 R2 NHCOCH3
11 31717 R1 R2 aziridinyl
12 251728 R1morpholinyl; R2 F
Hall et al.
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(buffer A) containing 1% (vol/vol) Triton X-100, 1 mg ml1 lysozyme,
and a cocktail of protease inhibitors (Roche Diagnostics, Burgess Hill,
United Kingdom). The clarified lysate was passed through a Ni-NTA col-
umn (Qiagen, Crawley, United Kingdom) and recombinant protein
eluted using buffer A supplemented with 500 mM imidazole and 0.5%
(vol/vol) Triton X-100. The protein concentration was determined using
a BCA assay system (Thermo Fisher Scientific, Cramlington, United King-
dom) and the purity level confirmed by SDS-PAGE.
Flavin characterization. The flavin cofactor bound to trypanosomal
NTRs was established by determining the fluorescence spectrum in acidic
and neutral buffers (16). Purified protein was desalted and boiled for 5
min. In a total volume of 100l, clarified supernatants (90l) containing
0.5 mg NTR were mixed with 10l 50 mM NaH2PO4 (pH 7.6) or 1 M HCl
(final pH  2.2). The fluorescence profile for each treatment was then
determined using a Gemini Fluorescent Plate Reader [Molecular Devices
(UK) Ltd., Wokingham, United Kingdom] with excitation   450 nm
and emission   480 to 600 nm. The resultant patterns were compared
with profiles obtained using FMN and FAD standards.
Enzyme activity. NTR activity was measured using several electron
acceptors as the substrate. A standard reaction mixture (1 ml) containing
50 mM Tris-Cl (pH 7.5), 100 M NADH, and 100 M electron acceptor
was incubated at room temperature for 5 min. The background reaction
rate was determined and the assay initiated by addition of the trypano-
somal NTR (20 g). For reaction mixtures containing nitroimidazoles,
nitrobenzyl phosphoramides, or most quinones, activity was measured by
following the change in absorbance at 340 nm corresponding to NADH
oxidation (ε  6,200 M1 cm1), whereas for assays involving nitro-
furans, the direct reduction of the substrate itself was monitored at 435
nm for nifurtimox (ε 18,000 M1 cm1) or at 400 nm for nitrofurazone
and nitrofurantoin (ε  12,000 and 15,000 M1 cm1, respectively).
DCPIP reduction was measured by following the decrease in absorbance
at 600 nm (ε  21,000), and CB1954 activity was determined by the
increase in absorbance at 420 nm, corresponding to production of the
hydroxylamine (ε  1,200 M1 cm1). Kinetic analysis was performed
using GraphPad Prism 5 software.
RESULTS
Trypanosomal type I nitroreductases are FMN binding pro-
teins. Based on cofactor and oxygen sensitivity, NTRs can be di-
vided into two groups: type I and type II (45). To evaluate which
class the trypanosomal enzymes fall into, recombinant protein
containing the catalytic domains from T. brucei or T. cruzi NTR
was expressed in E. coli and purified after one round of affinity
chromatography (Fig. 1A). Elutions containing recombinant pro-
teins were yellow, and analysis of their absorbance spectra identi-
fied peaks at 370 and 461 nm (Fig. 1B), both characteristic of flavin
binding type I NTRs (62, 67, 68). To determine the nature of the
NTR/cofactor interaction and identify which flavin was present,
recombinant protein (TbNTR and TcNTR) was denatured and
the fluorescence profile of supernatants analyzed. Flavin was re-
leased from both enzymes, indicating a noncovalent association
with the protein backbone (9, 62, 68), and the fluorescence pro-
files under conditions of neutral and acidic pHs identified FMN as
a cofactor (Fig. 1C); at neutral pH and excitation at 450 nm, flavin
derived from TbNTR and TcNTR had a peak emission at 535 nm,
representing a signal quenched under acidic conditions, typical of
FMN and distinct from FAD (Fig. 1C) (16).
The overall level of conservation among type I NTRs is low,
although certain key residues are highly conserved. Comparison
of the trypanosomal enzymes with their bacterial counterparts
identified several such amino acids, including R90, K94, and R302,
which may play a role in FMN binding, and Q124, which could
influence interactions with the substrate (note that the numbering
FIG 1 Trypanosomal NTRs contain FMN as a cofactor. (A) Coomassie-stained SDS-PAGE gel (10%) containing purified, recombinant TbNTR (lane 2). Lane
1, size standards. (B) Absorption spectrum (300 to 550 nm) of purified TbNTR (2 mg) in 50 mM NaH2PO. (C) Fluorescence spectra of FMN and FAD (both 25
M) and of supernatant from boiled and purified recombinant TbNTR (0.45g) at pH 7.6 (solid line) and pH 2.2 (dashed line) with excitation  at 450 nm and
emission  between 480 and 600 nm. All the fluorescence analyses were carried out in triplicate; the profiles are derived from the mean values. When TcNTR was
used in place of TbNTR, similar absorption and fluorescence profiles were observed.
Antiparasitic Activity of Aziridinyl Benzoquinones
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is in accordance with the TcNTR sequence) (Fig. 2A) (44, 49). To
evaluate the importance of these four residues in TcNTR activity,
they were converted to alanine and His-tagged mutant proteins
purified by affinity chromatography on a Ni2-NTa column. After
determination of the size and purity of each protein by SDS-
PAGE, activity was monitored using nifurtimox as a substrate
(Fig. 2B). In one mutant (R90A), a complete loss of NTR activity
was observed, and this correlated with a total loss of FMN binding
(Fig. 2C). The other three mutants all showed a partial (60% to
75%) inhibition of reductase activity but no significant change in
their FMN binding capacity (Fig. 2B and C). Presumably, the K94,
Q124, and R302 residues play some role in substrate (either
NADH or nitroaromatic) binding.
Substrate preference of the trypanosomal NTRs. To investi-
gate their substrate specificity, trypanosomal NTR activity was
monitored by following NADH oxidation at 340 nm or, when a
compound’s absorbance spectra precluded this, by following re-
duction of the substrate itself (Fig. 3A). This demonstrated that
both TbNTR and TcNTR functioned as typical bacterial type I
NTRs, able to catalyze the aerobic reduction of a wide range of
nitroaromatics and quinones (Table 2). For some 5-nitroimidaz-
ole compounds, such as the metronidazole-like drugs and a PA-
824-based antituberculosis agent, no or low activity was detected
using either of the parasite enzymes whereas other structures, such
as those of the anti-Chagas’ disease drugs nifurtimox and ben-
FIG2 Site-directed mutagenesis of TcNTR. (A) Schematic of TcNTR from T. cruzi Silvio X10/6 showing the amino-terminal extension (residues 1 to 79), FMN binding
motifs (residues 87 to 97 and 297 to 305), and substrate binding regions (residues 119 to 129) (44, 48, 65). Residues selected for mutagenesis are in bold, with arrows
indicating the new amino acid substitution. Numbers refer to positions of amino acids in the TcNTR sequence (GenBank accession no. EFZ30370). (B) NTR activity was
determined by following the reduction of nifurtimox (0 to 100M) at a fixed concentration of NADH (100M) in the presence of purified wild-type (WT) or mutant
TcNTR protein (4g). All assays were carried out in triplicate. The apparent Vmax for each protein was calculated, and the results are presented as a percentage of the
wild-type activity standard deviation. (C) The flavin recovered from the boiled, clarified supernatants of purified wild-type or mutant TcNTR (0.45g) was identified
as described for Fig. 1. The fluorescence of each supernatant was measured at pH 7.6 using excitation   450 nm and emission   535 nm. For each protein, the
fluorescence value from three independent readings was taken, and the data are presented as a percentage of the wild-type value standard deviation.
FIG 3 Investigating the kinetic properties of trypanosomal type I nitroreductase
toward quinones. (A) Proposed scheme for the reduction of quinone- and ni-
troaromatic-based substrates by NTRs using NADH as the electron donor; “red”
represents the reduced and “oxid” the oxidized form of the compound. The inter-
actions of the trypanosomal NTR with NADH (reaction I) and the substrate (re-
action II) are indicated. (B) NTR activity was assayed by following the reduction of
DCPIP at 600 nm. In reaction I, assays were carried out using different concentra-
tions of NADH (0 to 100M) in the presence of DCPIP (0.5 [], 1.0 [], and 2
[]M) and TcNTR (20g). In reaction II, NTR activity was assayed by follow-
ing the reduction of various concentrations of DCPIP (0 to 2M) in the presence
of NADH (20 [], 40 [], and 60 [Œ]M) and TcNTR (20g). When TbNTR
was used in place of TcNTR, similar enzyme kinetic profiles were observed.
Hall et al.
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znidazole, were metabolized at equivalent rates (Table 2). The
biggest difference between the two trypanosomal enzymes related
to their ability to reduce nitrobenzyl-based substrates. The aziridi-
nyl dinitrobenzamidine CB1954 and the two nitrobenzyl phos-
phoramide mustards LH7 and LH37 were more readily metabo-
lized by TbNTR than by TcNTR. In the case of the mustards, this
property has been shown to extend to trypanocidal activity: LH37
displays considerable growth-inhibitory activity against BSF T.
brucei, yielding an IC50 of 7 nM, whereas in studies of its activity
against intracellular T. cruzi, an IC50 140-fold higher (0.99 M)
has been reported (28, 32).
When the specific activity generated by a given substrate is
compared with its affinity toward the enzyme (Kcat/Km), both
trypanosomal NTRs appear to have a preference for quinones over
nitroaromatics: TbNTR exhibited an apparent Kcat/Km for ubiqui-
none 5 (coenzyme Q1) of 1.6 106, whereas for nifurtimox and
benznidazole, values of 9.2  103 and 6.1  103 M1s1 were
calculated, respectively. Such preferential reduction of quinoid
compounds is common among bacterial type I NTRs (9, 40, 67,
68). Interestingly, TbNTR could use NADPH and NADH as elec-
tron donors, although the apparent Km values indicate a prefer-
ence for NADH: using nifurtimox (100 M) as the substrate,
TbNTR had an apparent Km value of 71M for NADH compared
to 198 M for NADPH. In contrast, TcNTR could use only
NADH as a reductant, with a Km of 86 M (65).
To further investigate the type of kinetics that the parasite
NTRs display toward NADH, assays were carried out using vari-
ous concentrations of reductant against a fixed concentration of
substrate (Fig. 3B shows data relating to TcNTR reduction of
DCPIP; similar results were obtained using TbNTR). For most
substrates, double-reciprocal plots were linear at all concentra-
tions of electron acceptor, with the slopes remaining parallel, a
pattern characteristic of a ping-pong mechanism. Likewise, recip-
rocal assays using a fixed concentration of NADH and various
amounts of substrate generated a similar pattern of parallel slopes
(Fig. 3B). This mechanism of kinetics, typical for oxidoreductase
cascades, has previously been observed when using benznidazole
as an electron acceptor under normoxic conditions but not when
employing nifurtimox as the substrate (26, 27). When reduced by
the trypanosomal NTRs, this 5-nitrofuran forms a cytotoxic open
chain nitrile while undergoing limited futile cycling. No oxygen
consumption was detected during the reduction of the quinone
derivatives studied here (data not shown), suggesting that such
reactions, if they do occur, are negligible when using these com-
pounds as the substrate.
Like NAD(P)H:quinone oxidoreductases, bacterial type I NTRs
are highly susceptible to inhibition by dicoumarol (36, 40, 56).
When using NADH and nifurtimox (both at 100 M) as the
electron donor/acceptor, dicoumarol inhibited TbNTR activ-
ity with a Ki of 14 nM (Fig. 4A), indicating that this parasite
enzyme is particularly sensitive to the 4-hydroxycoumarin de-
rivative. TcNTR was less sensitive, with a Ki of 258 nM. Double-
reciprocal plots indicated that inhibition was competitive for
NADH (Fig. 4B).
TABLE 2 Substrate specificity of trypansomal NTRsa
Substrate
TbNTR TcNTR
Apparent Vmax Apparent Km Kcat/Km Apparent Vmax Apparent Km Kcat/Km
Nitroimidazoles
Benznidazole 419.0 35.0 60.0 13.0 3.0 103 564.0 19 43.0 4.0 6.1 103
Megazol 476.0 21.0 5.0 1.0 4.0 104 1,358.0 78.0 22.0 3.0 2.7 104
Metronidazole 93.0 9.0 55.0 13.0 7.3 102 0
6-Amino PA824 0 0
Nitrofurans
Nifurtimox 349.0 22.0 41.0 7.0 3.6 103 457.0 9.0 22.0 2.0 9.2 103
Nitrofurazone 1,167.0 51.0 10.0 1.0 5.2 104 439.0 20.0 13.0 2.0 3.3 103
Nitrofurantoin 772.0 37.0 1.3 0.4 2.5 105 1,059.0 10.0 11.0 1.0 4.2 104
Nitrobenzyls
CB1954 318.0 103.0 41.0 25.0 3.5 103 56.0 4.0 151.0 2.0 1.5 102
LH7 245.0 35.0 80.3 25.0 1.3 103 25.0 2.0 20.0 8.0 5.3 102
LH37 1,238.0 48.0 2.8 0.4 1.8 105 151.0 13.0 5.0 3.0 1.3 104
Quinones
Ubiquinone 5 1,227.0 1.0 0.3 0.0 1.6 106 963.0 52.0 4.0 0.5 1.1 105
Duroquinone 852.0 56.0 2.0 0.5 1.5 105 384.0 27.0 10.0 2.0 1.6 104
DCPIP 999.0 183.0 3.0 1.5 1.4 105 1,172.0 40.0 0.4 0.1 1.2 106
a The apparent Vmax and Km ( standard deviation) TbNTR and TcNTR (20 g) values for various nitroaromatic and quinone-based substrates (0 to 200 M) were determined in
the presence of NADH (100 M). For all nitroimidazoles, LH7, LH37, ubiquinone 5, and duroquinone, activity was followed by monitoring the rate of NADH oxidation and the
kinetic values were calculated using ε 6,220 M1cm1. For nitrofurans, assays were carried out by following the direct reduction of the nitroheterocycle. Kinetic values were
calculated using ε 18,000, 12,000, or 15,000 M1cm1 for nifurtimox, nitrofurazone, or nitrofurantoin, respectively, and the amount of reductant consumed per reaction was
determined, assuming that 4 molecules of NADH are oxidized per molecule of nitrofuran reduced (26). In reactions using DCPIP as the substrate, direct reduction of the
indophenol was followed and activity determined using ε 21,000 M1cm1, assuming that 2 molecules of NADH are metabolized during reduction of 1 molecule of DCPIP (3).
For CB1954, activity was monitored by detecting production of the hydroxylamine. Kinetic values were determined using ε 1,200 M1cm1, and the amount of NADH oxidized
per reaction was determined, assuming that 4 molecules of reductant are turned over per molecule of CB1954 reduced (7, 50). The apparent Vmax values are expressed as
nanomoles of NADH oxidized per minute per milligram and apparent Km values in micromoles. The specificity constant (Kcat/Km), expressed in per molar per second, was
determined and assumed one catalytic site per 30-kDa monomer. Metronidazole was not a substrate for TcNTR (n/a no activity).
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Taken together, the FMN binding, aerobic activity, substrate
range, kinetics, and inhibition profiles of the two trypanosomal
NTRs confirm that both function as classic type I NTRs.
Aziridinyl benzoquinones as TbNTR substrates and trypano-
cidal agents. Aziridinyl benzoquinones have long been of interest
in the treatment of cancer. These compounds are activatable by
the enzyme NQO1, which is rarely expressed in most normal hu-
man tissues but is highly upregulated in many tumor cells. RH1
(compound 3), AZQ (compound 4), and TZQ (compound 5)
have been shown to be effective anticancer agents in preclinical
studies, with RH1 recently completing phase I trials (4, 14, 61). All
appear to induce cell damage primarily by DNA alkylation and
cross-linking following reductive activation (13, 66). To deter-
mine whether the trypanosomal NTR could activate aziridinyl
benzoquinones, a series of compounds (Table 1) were biochemi-
cally screened to determine whether they could drive NADH ox-
idation (fixed at 100 M) in the presence of TbNTR (20 g) (Ta-
ble 3). Under these conditions, seven compounds (compounds 1
to 6 and 12) were metabolized by TbNTR at respectable rates, with
some displaying high affinities for the enzyme, resulting in
Kcat/Km values ranging from 1.6 10
4 (compound 4) to 6.4 105
(compound 3). For the remaining compounds, two (compounds
9 and 10) generated relatively low activities, resulting in Kcat/Km
values equivalent to those determined using benznidazole and ni-
furtimox, while three (compounds 7, 8, and 11) were not metab-
olized.
All 12 compounds were then screened to determine whether
they displayed growth-inhibitory activity toward BSF T. brucei
(Table 4). For all except one (compound 8), IC50s	 10 M were
calculated. Those compounds that were poor TbNTR substrates
(compounds 7 to 11) generally displayed the highest IC50s, with
only the tetra-aziridinyl benzoquinone (compound 11) showing
significant antiparasitic activity (IC50 of 87 6 nM). All the other
compounds found to be effective TbNTR substrates (compounds
1 to 6 and 12) were also shown to have trypanocidal activities, with
IC50s ranging from 21 nM (RH1 [compound 3]) to 1.5M (AZQ
[compound 4]). To evaluate whether TbNTR plays a role in acti-
vating the six most potent aziridinyl benzoquinones (DZQ [com-
pound 1], MeDZQ [compound 2], RH1 [compound 3], TZQ
[compound 5], compound 6, and compound 11) within the par-
FIG 4 Inhibition of trypanosomal NTR quinone reductase activity by dicoumarol. (A) DCPIP (5 M) reduction by TbNTR (20 g) in the presence of NADH
(100 M) was readily inhibited by dicoumarol (0 to 200 nM). Inhibitory activity is expressed as a percentage compared to uninhibited control results. (B) NTR
activity was assayed by following DCPIP (5 M) reduction in the presence of NADH (0 to 100 M) and 0 (), 5 (), 10 (Œ), and 20 () nM dicoumarol. All
reactions were initiated by addition of TbNTR (20 g), and activity (v) is expressed in micromoles of DCPIP reduced per minute per milligram.
TABLE 3 Activity of TbNTR toward aziridinyl benzoquinonesa
Compound Apparent Vmax Apparent Km Kcat/Km
DZQ (1) 3,340.0 267.0 2.9 0.3 5.0 105
MeDZQ (2) 2,334.0 221.0 6.9 1.5 1.5 105
RH1 (3) 3,080.0 110.0 2.1 0.2 6.4 105
AZQ (4) 750.0 30.0 20.6 2.3 1.6 104
TZQ (5) 1,799.0 180.0 6.5 2.1 1.2 105
6 1,080.0 30.0 9.9 0.9 4.7 104
7 n/a
8 n/a
9 120.0 20.0 30.2 11.5 1.7 103
10 430.0 50.0 66.7 16.3 2.8 103
11 n/a
12 2,377.0 231.0 5.2 1.3 2.0 105
a The apparent Vmax and Km ( standard deviation) TbNTR (20 g) values for various
aziridinyl benzoquinone substrates (0 to 100 M) were determined in the presence of
NADH (100 M). TbNTR activity was followed by monitoring NADH oxidation, and
the kinetic values were calculated using ε 6,220 M1 cm1. The apparent Vmax
values are expressed as nanomoles of NADH oxidized per minute per milligram, and
apparent Km values are expressed in micromoles. The specificity constant (Kcat/Km),
expressed in per molar per second, was determined by assuming one catalytic site per
30-kDa monomer. Compounds 7, 8, and 11 were not metabolized by TbNTR (n/a no
activity).
TABLE 4 Trypanocidal activity of aziridinyl benzoquinonesa
Compound
T. brucei IC50 (nM)
Ratio
( tet/ tet)Wild type
Transformed
( tet)
Transformed
( tet)
DZQ (1) 272 1 318 38 90 3 3.5
MeDZQ (2) 698 57 740 18 115 3 6.4
RH1 (3) 21 1 12 2 3 1 4.0
AZQ (4) 1,590 110
TZQ (5) 179 1 184 10 60 9 3.1
6 283 41 310 40 140 20 2.2
7 7,733 1030
8 
10,000
9 2,450 328
10 6,293 15
11 87 6 121 21 148 9 0.8
12 1,253 77
a Data represent the growth-inhibitory effect (as judged by their IC50s) of aziridinyl
benzoquinones on wild-type T. brucei (Lister 427; clone 221a). For the six most potent
compounds, IC50s ( standard deviations [SD]) against parasites transformed to
express elevated levels of TbNTR under tetracycline (1 g ml1) control were also
determined. The data in columns 2 to 4 represent mean IC50s ( SD) determined in
growth assays performed in triplicate.
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asite, we made use of a cell line manipulated to express elevated
levels of the enzyme (65). This revealed that, with one exception,
cells induced to overexpress NTR were 2- to 6-fold more sensitive
to the prodrug (DZQ [compound 1], MeDZQ [compound 2],
RH1 [compound 3], TZQ [compound 5], and compound 6) than
noninduced controls (Table 4, Fig. 5). In only one case (com-
pound 11) did elevation of the NTR level fail to alter susceptibility,
presumably because that compound is not a substrate for this
enzyme (Tables 3 and 4).
DISCUSSION
Type I NTRs are a group of enzymes initially believed to be re-
stricted to bacteria. They typically contain FMN as a cofactor and
metabolize a wide range of nitroaromatic and quinone substrates
in a reaction that is not affected by oxygen (45, 62, 67, 68). It is now
clear that several eukaryotic protozoan parasites also express type
I NTRs, with these orthologs playing a key role in the activation of
the clinically used nitroaromatic prodrugs nifurtimox, benznida-
zole, and metronidazole (38, 41, 43, 65). Here, we report that the
trypanosomal enzymes noncovalently bind FMN, utilize NADH
as a reductant, and catalyze the reduction of a wide range of sub-
strates via a ping-pong mechanism, an activity readily inhibited by
dicoumarol. These properties are characteristic of their bacterial
counterparts.
A distinct feature displayed by all bacterial type I NTRs is their
ability to bind FMN as a cofactor, a characteristic shared by
TbNTR and TcNTR (Fig. 1) (9, 62, 68). Overall sequence conser-
vation between type I NTRs from different species (pro- and eu-
karyotic) is low, although some key residues are shared, with many
being implicated in cofactor binding (44, 49, 65). For the E. coli
nfsB sequence, nine residues located across five sites are involved
in cofactor interactions (44). Two of these sites, including a char-
acteristic R[S/T/A]X[R/H] amino-terminal cluster, mediate FMN
binding via the ribityl chain. Two further regions mediate inter-
actions via the isoalloxazine tricyclic ring, and the fifth attaches to
FMN=s phosphate grouping. Of these, five amino acids (R90, S92,
K94, E260, and R302 [numbering based on TcNTR]) found at
three locations are also present in the two trypanosomal enzymes.
Site-directed mutagenesis of TcNTR revealed that only one of the
mutations, R90A, prevented cofactor interaction and generated
an inactive enzyme (Fig. 2). This is the only invariable residue in
an amino-terminal cluster present in all nfsB-like type I NTRs
from different origins, suggesting the universal importance of this
arginine in FMN binding and NTR activity. In bacterial nfsB-like
enzymes, reduced NTR activity in vivo contributes to drug resis-
tance, with residues equivalent to K94, Q124, and R302 implicated
in this process (53, 63). Alterations at these sites generated mutant
proteins that bound FMN at levels equivalent to those seen with
the wild type but exhibited significantly reduced enzymatic activ-
ities (Fig. 2). As K94 and R302 represent two of the residues con-
served between nfsB and TcNTR, as noted above, we initially pre-
dicted that conversion of the lysine or arginine to alanine at either
site would affect cofactor binding. This clearly is not the case, and
our results suggest that if K94 or R302 or both are involved in
TcNTR/FMN binding, then their contribution to this interaction
is secondary to that of R90, with a single mutation at either site
insufficient to block attachment.
The spectrum of compounds that TcNTR and TbNTR can me-
tabolize is typical of that reported for other type I NTRs, although
there are slight differences in substrate specificity (Table 2) (9, 40,
62, 67, 68). For example, 5-nitroimidazoles such as metronidazole
are not readily metabolized by either of the trypanosome enzymes
whereas they are efficiently reduced by bacterial and other proto-
zoal type I NTRs (24, 39, 43). When the substrate ranges of the two
trypanosomal reductases are contrasted, the two enzymes yielded
equivalent specificity constant values for 2-nitroimidazoles, 5-ni-
trofurans, and DCPIP. However, they can be distinguished based
on their ability to reduce nitrobenzyls and benzoquinones, with
TbNTR generating specificity constant values 10-fold higher
than TcNTR toward the azirinidyl dinitrobenzamidine CB1954,
the nitrobenzyl phosphoramide mustards LH7 and LH37, and the
1,4-benzoquinones ubiquinone 5 and duroquinone. Such dispar-
ities are not unexpected, as relatively small sequence variations
can have a profound impact on substrate preference: alteration of
two amino acids in the E. coli nfsB sequence is sufficient to en-
hance its ability to activate CB1954 by 100-fold (35). Despite these
differences, based on specificity constant values, quinone-based
compounds generally represent the preferred substrate for both
TcNTR and TbNTR (Table 2).
The biological role of the trypanosomal NTRs is unknown.
However, targeted gene deletion studies have clearly shown that
they are essential to mammalian infective trypanosomes, as BSF
TbNTR null mutants cannot be generated (65). Likewise, T. cruzi
insect-form TcNTR null mutants are unable to differentiate into
infectious metacyclic trypomastigotes and cannot infect mamma-
lian cells (65). Based on their mitochondrial location and prefer-
ence for quinone-based substrates, coupled with their similarity to
FMN-dependent NADH dehydrogenases, enzymes that mediate
reduction of ubiquinone to ubiquinol, the trypanosomal type I
NTRs may function as ubiquinone reductases. T. brucei insect
forms are reported to express several distinct ubiquinone reduc-
tases, but only two activities have been identified in BSF parasites
(17–20, 25, 55). One is attributed to GPDH and the second to
FIG 5 Susceptibility of bloodstream-form T. brucei to aziridinyl benzoquino-
nes. IC50 values of the most potent aziridinyl benzoquinones on T. brucei cells
induced to express elevated levels of TbNTR (black bars) compared to nonin-
duced control values (white bars) are shown. Data represent means standard
deviations (SD) of the results of four experiments, and the differences in sus-
ceptibility for DZQ (compound 1), MeDZQ (compound 2), RH1 (compound
3), TZQ (compound 5), and compound 6 were statistically significant (P 	
0.01), as assessed by Student’s t test.
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an uncharacterized enzyme. The difference between the parasite
forms is associated with the lack of cytochrome-dependent re-
spiratory chains in the mammalian infective stage (6, 58, 59).
However, T. brucei BSFs do possess a non-cytochrome-depen-
dent terminal oxidase, the trypanosomal alternative oxidase
(TAO), which, in concert with GPDH, functions to transfer
reducing equivalents from cytosol/glycosome-generated NADH via
ubiquinone to O2, to produce H2O (6, 10, 12). This cascade plays
a key role in energy metabolism by maintaining the cytosolic/
glycosomal NADH/NAD balance. Potentially, TbNTR may ful-
fill a similar role in the parasite’s single mitochondrion, helping to
maintain the NADH/NAD balance in this organelle. As such, it
may represent the “enigmatic” BSF NADH:ubiquinone oxi-
doreductase activity whose presence has been vigorously debated
(55). Interestingly, deep sequence analysis of T. brucei populations
selected for nifurtimox resistance using a whole-genome loss-of-
function screen provided further evidence to link TbNTR activity
with ubiquinone availability, giving additional credence to the
hypothesis that the biological function of TbNTR is as a ubiqui-
none reductase (1). Whether this pathway functions in T. cruzi is
unclear. The mitochondrial energetics of this parasite is less well
characterized than that of T. brucei, particularly regarding the in-
tracellular stage. T. cruzi does not express a direct homologue of
TAO but does possess a gene that has the potential to encode
a mitochondrially targeted alternative oxidase-like protein
(GenBank accession number EAN97989). However, this en-
zyme lacks certain key features that typify this class of oxidase, and
its activity has yet to be confirmed.
The marked preference of the trypanosomal NTRs for quinone
substrates suggests that this class of compound might represent an
alternative to nitroheterocycles for the treatment of Chagas’
disease and/or HAT. Quinones are widely used in medicine as
anti-infection and anticancer agents. Trypanocidal screens us-
ing natural and synthetic quinones have shown that com-
pounds of this class have potential as antiparasitic agents, al-
though how these mediate their activity remains unclear. Here,
we evaluated whether a series of aziridinyl benzoquinone deriva-
tives, anticancer prodrugs designed to undergo activation by the
human NQO1, displayed growth inhibitory properties against
BSF T. brucei and then determined if TbNTR played a role in this
activity. All compounds tested contained a 1,4-benzoquinone
backbone and two aziridinyl groups at the 2 and 5 positions (Table
1). For most structures, the 3 and 6 positions contained equivalent
substitutions (e.g., H for DZQ [compound 1], CH3 for MeDZQ
[compound 2], etc.), although in three cases divergent groupings
were present (e.g., CH2OH and CH3 in RH1 [compound 3],
aziridinyl and H in TZQ [compound 5], or morpholinyl and F in
compound 12). Several compounds were identified as the sub-
strates for the parasite enzyme, generating specificity constants
100-fold higher than those of nifurtimox and benznidazole (Ta-
bles 2 and 3), with RH1 (compound 3) yielding the highest spec-
ificity constant. Although no structure activity relationship could
be determined from this limited biochemical screen, compounds
containing amine-linked substitutions at positions 3 and 6 on the
benzyl backbone were generally the poorest substrates for the par-
asite enzyme. In tests performed with T. brucei, the biochemical
data translated into trypanocidal activity (Table 4) such that the
best TbNTR substrates were the most potent against the parasite:
the most effective aziridinyl quinone was RH1 (compound 3),
which yielded an IC50 of 21 nM. The exception to this pattern was
the tetra-aziridinyl benzoquinone (compound 11), which, al-
though inactive in the biochemical assays, displayed significant
potency (IC50 of 87 nM) against infection-form parasites. To con-
clusively demonstrate the link between reductase and trypano-
cidal activities, susceptibility to the most effective compounds was
investigated using parasites engineered to overexpress TbNTR
(Table 4; Fig. 5). For five of the six compounds tested, trypano-
somes with elevated levels of the TbNTR were more susceptible to
the aziridinyl benzoquinone than controls, indicating that this
enzyme can activate those agents in vivo. The only quinone that
failed to elicit a difference was the tetra-aziridinyl benzoquinone
(compound 11), which was not metabolized by TbNTR in vitro.
We have now shown that the trypanosome enzymes which
activate the clinically used prodrugs nifurtimox and benznidazole
display many of the characteristics typical of bacterial type I NTRs:
they are FMN-containing proteins that reduce a wide range of
substrates via an oxygen-insensitive activity that can be readily
inhibited by dicoumarol. Based on substrate preference, the
trypanosomal type I NTRs can be regarded as quinone (possibly
ubiquinone) reductases. We have exploited this characteristic to
identify several aziridinyl benzoquinones that display significant
antitrypanosomal properties. Understanding how these parasite
enzymes mediate their biological function may therefore contrib-
ute to the development of novel prodrugs with improved selectiv-
ity and pharmacokinetic properties compared to those currently
available.
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